Pre-Exposure Prophylaxis against HIV in Primary Care. September 2017 Update. John-Paul Bettencourt, D.O., M.P.H., AAHIVS
|
|
- Howard Mason
- 6 years ago
- Views:
Transcription
1 John-Paul Bettencourt, D.O., M.P.H., AAHIVS Pre-Exposure Prophylaxis against HIV in Primary Care September 2017 Update
2 Continuing Medical Education Disclosure Program Faculty: John-Paul Bettencourt, DO, MPH, AAHIVS Financial Disclosure: No relationships or conflicts. Off-Label Use: This presentation does not include off-label products or treatments.
3 tinyurl.com/ 2017UNECOM
4 Informing Guidelines Centers for Disease Control and Prevention: US Public Health Service: Preexposure Prophylaxis for the Prevention of HIV Infection in the United States 2014 Clinical Practice Guideline Centers for Disease Control and Prevention: US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States 2017 Update: a clinical practice guideline. Updated September Centers for Disease Control and Prevention: US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States 2014: clinical providers supplement. Centers for Disease Control and Prevention: US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States 2017 Update: clinical providers supplement. Updated September 2017.
5 Case Study Joe is a 27 year-old generally healthy male presents to establish care. 2 day Hx of acute onset cold with fever, sore throat, and swollen glands with multiple sick contacts at work, no flu shot Tx with frequent ibuprofen MSM with unprotected anal sex with 1 primary and 2 occasional sex partners Last unprotected sexual encounter 10 days ago 4 th Gen HIV Ab/Ag test negative Next step?
6 Objectives Review current demographics of at-risk populations and current trends of new HIV Infections Review Indications, Testing/Timeline, and Refill protocols for PrEP against HIV medication Review Non-Occupational Post Exposure Prophylaxis (npep) protocol if patient is exposed to HIV Briefly review current state of HIV Treatment
7 Signs and Symptoms of Acute HIV Fever 75% Fatigue 68% Myalgia 49% Skin rash 48% Headache 45% Pharyngitis 40% Cervical LAD 39% Arthralgia 30% Night sweats 28% Diarrhea 27%
8 Current state of HIV 1.1 million people in the US are living with HIV 15% of them don t know it. Young people were the most likely to be unaware of their infection. 44% of y/o did not know they were living with HIV. CDC. Singh S, Song R, Johnson AS, McCray E, Hall HI. HIV incidence, prevalence, and undiagnosed infections in men who have sex with men. Presented at Conference on Retroviruses and Opportunistic Infections; February 14, 2017; Seattle, WA.
9 New HIV Infections 39,513 new HIV infections (2015) 67% were among homosexual (MSM) or bisexual (MSWM) 24% were among heterosexual (MSW/WSM) 3% were among people who inject drugs (PWID)
10 From 2010 to 2014: Overall estimated number of annual HIV infections declined 10% Among PWID, annual infections declined 32% Among heterosexuals, annual infections declined 23%. Among gay and bisexual men, trends varied by race and age: White gay/bisexual men: declined 11%. Black/African American gay/bisexual men: infections remained stable. Hispanic/Latino gay/bisexual men: increased 14%. Gay and Bisexual men aged 13-24: Declined 16% Gay and Bisexual men aged 25-34: Increased 23% Gay and Bisexual men aged 35-44: Declined 16%
11 New HIV Diagnoses in the United States for the Most-Affected Subpopulations, 2015 (CDC)
12 Time to act Each year, approximately 50,000 people are diagnosed with HIV infection in the United States, and many others are at risk Men who have sex with men and transgender women face an especially high risk of becoming infected with HIV. This is an opportunity to prevent HIV by offering preexposure prophylaxis (PrEP) to people with a high risk of infection.
13 What is PrEP against HIV? A biomedical intervention consisting of a daily, oral antiretroviral medication that is >90% effective if taken regularly by people who are HIV-uninfected but at risk of infection Currently, the only medication licensed for PrEP in the United States is the once-daily tablet tenofovir disoproxil fumarateemtricitabine (TDF-FTC, also called Truvada). Other PrEP medications and formulations are being developed, but they are not yet available for clinical use in the United States.
14 Who is high risk? Men who have Sex with Men (MSM) Condomless anal sex Recent sexually transmitted infection HIV-infected partner Heterosexual adults Condomless sex with a partner who injects drugs Comdomless sex with a bisexual man HIV-infected partner Injection drug users Use of shared injection equipment Preexposure prophylaxis for the prevention of HIV infection in the United States CDC. Available from:
15 How well does PrEP work?
16 PrEP Clinical Trial Results iprex Study: Among gay and bisexual men, those who were given PrEP were 44% less likely overall to get HIV than those who were given a placebo. Of participants with detectable levels of medicine in their blood, PrEP reduced the risk of infection by as much as 92%. ( Partners PrEP Study: Among men and women in HIV discordant couples, those who received PrEP were 75% less likely to become infected than those on placebo. Among those with detectable levels of medicine in their blood, PrEP reduced the risk of HIV infection by up to 90%. ( Bangkok Tenofovir Study: Among injection drug users, a once-daily tablet containing tenofovir (one of the two drugs prescribed in Truvada) reduced the risk of getting HIV by 49%. For participants who had detectable tenofovir in their blood, risk of infection reduced by 74%. ( No significant safety concern with use of daily oral PrEP was found in any study.
17 History July 2012: FDA approves the combination pill Truvada for use as PrEP. Gilead Sciences report on the estimated number of U.S. residents going on PrEP for the first time per quarter between 2012 and (FTC/TDF is shorthand for Truvada.) Note the steady increase launching in late 2013.Gilead Sciences.
18 Use of PrEP against HIV >79,000 people in the US have started Truvada Mean age was 36 years California, New York, Texas, Florida and Illinois accounted for just over half of all prescriptions But a smaller state Massachusetts had the highest percentage of its residents on PrEP, at 0.073%
19 How are we doing? 1.2 million Americans are likely to benefit from using HIV pre-exposure prophylaxis (PrEP) 1 in 4 sexually active MSM...492,000 1 in 5 persons who inject drugs 115,000 1 in 200 heterosexual adults..624, million Americans are indicated to use PrEP against HIV BUT ARE NOT TREATED Smith MMWR 2015; McCallister IAS 2016
20 What that means 1,200,000 people indicated for PrEP 79,000 people are prescribed
21 How to Prescribe PrEP against HIV
22 Determine eligibility for PrEP against HIV Document high risk of HIV infection based sexual and medical history. Assess ability/willingness to adhere to regular visits, testing, and daily medication. Confirm that the patient is HIV-uninfected preferably a fourth-generation HIV antibody-antigen test. No s/s of acute HIV infection in the previous 4 weeks Positive symptoms HIV RNA ( viral load ) Confirm that creatinine clearance >60 ml/min Assess for chronic hepatitis B infection by sending a hepatitis B surface antigen test (HBsAg). Assess pregnancy status in patients with childbearing potential.
23 ASSESSING RISK OF SEXUAL HIV ACQUISITION 76% of MSM surveyed in 2008 in 21 US cities reported a health care visit during the past year BUT studies report that health care providers do not ask about, and patients often do not disclose, same-sex or high-risk sexual behaviors. Were you sexually active within the past 6 months? With males, females, or both? What % of the time was a condom used? Do you practice ANY anal sex?
24 Oral PrEP Knowledge and Experience 2016 MSM online survey, n=4,638 Heard of PrEP 78.2% Taken PrEP 14.9% Ability to adhere to PrEP Very easy 80.0% Somewhat easy 11.4% Somewhat or very difficult 4.0%
25 Prescribe PrEP against HIV Prescribe once-daily, oral fixed-dose combination tablet Truvada consisting of 300 mg of tenofovir disoproxil fumarate and 200 mg of emtricitabine (TDF-FTC) CDC recommends prescribing no more than a 90-day supply so that patients do not continue the medication long term without appropriate clinical and laboratory monitoring.
26 Patient Instructions for Truvada Take as a daily dose No diet change required If dose is forgotten, take as soon as remembered unless it is almost time for the next dose (DO NOT DOUBLE DOSE) Take on a full stomach or before bed
27 Truvada Risks Kidney problems, including kidney failure. Your healthcare provider may do blood tests to check your kidneys before and during treatment with TRUVADA. If you develop kidney problems, your healthcare provider may tell you to stop taking TRUVADA. Too much lactic acid in your blood (lactic acidosis), which is a serious but rare medical emergency that can lead to death. Tell your healthcare provider right away if you get these symptoms: weakness or being more tired than usual, unusual muscle pain, being short of breath or fast breathing, stomach pain with nausea and vomiting, cold or blue hands and feet, feel dizzy or lightheaded, or a fast or abnormal heartbeat. Severe liver problems, which in rare cases can lead to death. Tell your healthcare provider right away if you get these symptoms: skin or the white part of your eyes turns yellow, dark "tea-colored" urine, light-colored stools, loss of appetite for several days or longer, nausea, or stomach-area pain. Bone problems, including bone pain, softening, or thinning, which may lead to fractures. Your healthcare provider may do tests to check your bones. Worsening Hepatitis B infection
28 Risks - BONE HEALTH Decreases in bone mineral density (BMD) have been observed in HIV-infected persons treated with combination antiretroviral therapy (including TDF-containing regimes) Studies show a ~2% decrease in bone density with no increase in fragility (atraumatic) fractures over the 1-2 years of observation Therefore, DEXA scans or other assessments of bone health are NOT recommended before initiation, or monitoring, of persons taking PrEP However, any person being considered for PrEP who has a history of pathologic or fragility bone fractures or who has significant risk factors for osteoporosis should be referred for appropriate consultation and management.
29 Costs to the Patient PrEP against HIV is covered by most insurances Gilead Sciences has an Assistance Program Annual Out-of-Pocket expenses include at least four office visit (preventive counseling), lab, and prescription co-pays In 2012, NY DOH estimated that Truvada for PrEP costs $8,000-$14,000 per year (
30 Truvada Side Effects Nausea/Diarrhea/Flatulence (abdominal pain/weight loss) Rash Headache/Dizziness Abnormal dreams/problems sleeping/tiredness Depression Symptoms usually resolve within 2 weeks to 2 months Only 44% of PrEP users reported any side effects
31 Monitor PrEP against HIV Send an HIV antibody/antigen test at least every 3 months. Suspicion for acute HIV infection HIV RNA Viral Load Check pregnancy status every 3 months. There are no known safety concerns with PrEP use in pregnancy; however, data on this subject are limited. Check a serum creatinine after 3 months and, if stable, every 6 months thereafter. Perform STI screening (syphilis antibody, nucleic acid amplification testing for gonorrhea and chlamydia at all sites that could have been exposed) at least every 6 months. Evaluate continued appropriateness for PrEP on at least an annual basis.
32 Follow-up Office visits Patients should return for follow-up every 3 months. I recommend pre-scheduling at least 2 visits (6 months) Clinicians may wish to see patients more frequently at the beginning of PrEP 1 month after initiation, to assess and confirm HIV-negative test status, assess for early side effects, discuss any difficulties with medication adherence, and answer questions. Clinicians may wish to see patients more frequently who are engaged in multiple high-risk behaviors.
33 Mitigate Risks Counsel about adherence to protocol and risk reduction at every visit. Recommend reduction in sexual partners Recommend reduction in other high risk behaviors (EtOH abuse, illicit drug use, sex work, trauma-inducing sexual activity) Reassess the need for PrEP against HIV at least once per year PRACTICE SAFE SEX!!!
34 HIV Testing Documentation of results are required to confirm that patients do not have HIV infection when they start taking PrEP medications. For patient safety, HIV testing should be repeated at least every 3 months (before prescriptions are refilled or reissued). This requirement should be explained to patients during the discussion about whether PrEP is appropriate for them. CDC & USPHTF recommend that MSM, IDUs, patients with a sex partner who has HIV infection, and others at substantial risk of HIV acquisition undergo an HIV test at least annually or for those with additional risk factors, every 3-6 months. Outside the context of PrEP delivery, testing is often not done as frequently as recommended.
35 HIV Testing At a minimum, clinicians should document a negative antibody test result within the week before initiating (or reinitiating) PrEP medications. The required HIV testing can be accomplished by (1) drawing blood (serum) and sending the specimen to a laboratory for a routine HIV EIA (enzyme-linked immunoassay) or (2) performing a rapid, point-of-care, FDA-approved, fingerstick blood test. Oral rapid tests should not be used to screen for HIV infection when considering PrEP use because they can be less sensitive than blood tests. Clinicians should not accept patient-reported test results or documented anonymous test results. A preliminary positive HIV antibody test must be confirmed by Western blot or IFA (immunofluorescence assay) according to the local laboratory standard practice and viral load and CD4 lymphocyte tests should be ordered to assist in future treatment decisions.
36 HIV Resistance iprex Treatment Group iprex Control Group 2 infected at baseline 2 resistant viruses 8 infected at baseline 1 resistant virus 36 infected after baseline 0 resistant viruses 64 infected after baseline 0 resistant viruses
37 PrEP Failures 43-yr-old MSM 24 mos, supported by pharmacy records, blood concentration analyses, and clinical history Acquired MDR HIV infection Exposure to PrEP-resistant, multiclass-resistant HIV strain MSM in his 20s Excellent compliance by self report, supported by blood and hair concentration analyses Acquired MDR HIV infection after 2 instances of condomless insertive anal intercourse with 2 different partners within 11 weeks before diagnosis Exposure to PrEP-resistant, multiclass-resistant HIV strain 50-yr-old MSM Excellent by self report, supported by blood analyses Acquired wild-type HIV infection after 2-5 median condomless anal sex partners per day in each month following PrEP initiation Chronic rectal inflammation +/- Trauma Knox DC, et al. CROI Abstract 169aLB.; Grossman H, et al. HIVR4P Abstract OA03.06LB.; Hoornenborg E, et al. CROI Abstract 953
38 Do NOT use other antiretroviral regimens or other medications in lieu of Truvada other than daily dosing of Truvada e.g., intermittent, episodic [pre/post sex only], or other discontinuous dosing PrEP as expedited partner therapy i.e., do not prescribe for an uninfected person not in your care other renal active medications in excess. Acyclovir, valacyclovir, cidofovir, ganciclovir, valganciclovir, aminoglycosides, high-dose or multiple NSAIDS or other drugs that reduce renal function or compete for active renal tubular secretion Serum concentrations of these drugs and/or TDF may be increased. Monitor for dose-related renal toxicities.
39 TIME TO ACHIEVING PROTECTION Maximal protection against HIV infection is unknown. There is not scientific consensus on what intracellular concentrations are protective for either drug or the protective contribution of each drug in specific body tissues. The pharmacokinetics of TDF and FTC vary by tissue. Pharmacokinetic studies suggest maximum tissues levels occur in: rectal tissue after approximately 7 days blood and cervicovaginal tissues after approximately 20 days No data are yet available about intracellular drug concentrations in penile tissues susceptible to HIV infection
40 My talking points with a new patient PrEP efficacy and importance of adherence Side effects: GI, renal, bone PrEP does not protect against other STIs except perhaps HSV (Celum, Ann Intern Med, 2014). Periodic HIV testing, creatinine checks, and office visits are mandatory. The risk of HIV drug resistance if he/she becomes infected with HIV while on PrEP What we think about time to maximal protection, time to continue after last high-risk encounter 40
41 My talking points with a new patient Nausea may occur with initiation of tenofovir-emtricitabine; it typically resolves with time. Kidney injury occurs rarely (2% in iprex). Periodic monitoring is obligatory. Abnormalities usually resolve with drug discontinuation. A small decrease in bone mineral density may occur; the clinical significance of this is unknown. Antiretroviral resistance is unlikely but possible and so strict adherence to the testing/visit protocol is critical PrEP is ONLY PART of the answer to reduce the risk of HIV transmission
42 Efficacy with 95% CI Adherence is Key Any >50% >90% + Drug Levels Compliance with Daily Dosing iprex
43 Improving Compliance with PrEP Monitor medication adherence in a non-judgmental manner Normalize occasional missed doses, while ensuring patient understands importance of daily dosing for optimal protection Reinforce success Assess side effects and plan how to manage them Identify and address factors that interfere with adherence Use a multidisciplinary/team approach (reminders at nursing visits, etc.)
44 Discontinuing PrEP Patients may discontinue PrEP medication for several reasons personal choice, changed life situations resulting in lowered risk of HIV acquisition, intolerable toxicities, chronic nonadherence to the prescribed dosing regimen despite efforts to improve daily pill-taking, or acquisition of HIV infection. Upon discontinuation document in the health record: HIV status at the time of discontinuation Reason for PrEP discontinuation Recent medication adherence and reported sexual risk behavior If resuming PrEP, repeat all the same pre-prescription evaluations as the initial workup.
45 Non-Occupational Post Exposure Prophylaxis (npep) Persons not receiving PrEP who seek care within 72 hours after an isolated sexual or injection-related HIV exposure should be evaluated for the potential need for npep. If such exposures are not isolated, and the person is determined not to have HIV infection, clinicians should consider beginning PrEP immediately because PrEP during the first 28 days is consistent with a recommended npep regimen.
46 Non-Occupational Post Exposure Prophylaxis (npep) If the exposure is isolated (e.g., sexual assault, infrequent condom failure), npep should be prescribed, but continued antiretroviral medication is not indicated after completion of the 28-day PEP course. Persons who repeatedly seek npep should be evaluated for possible PrEP use after confirming they have not acquired HIV infection. Because HIV infection has been reported in association with exposures soon after an npep course, daily PrEP may be more protective than repeated episodes of npep.
47 npep + PrEP Patients fully adhering to a daily PrEP regimen do not need npep if they experience a potential HIV exposure while on PrEP. PrEP is highly effective when taken daily or near daily For patients who report that they take their PrEP medication sporadically and those who did not take it within the week before the recent exposure, initiating a 28-day course of npep might be indicated All npep baseline and follow-up laboratory evaluations should be conducted. After the 28-day npep regimen is completed, if confirmed to be HIV uninfected, the daily PrEP regimen can be reinitiated.
48 npep Protocol
49 Future of PrEP Against HIV Injectable PrEP Daily oral Truvada vs. injectable Cabotegravir 4 year-long study The study is enrolling 18+ y/o HIV uninfected cisgender MSM and transgender women The Fenway Institute is 45% enrolled (although this changes nearly daily!) and enrollment is competitive so enrollment will continue past goal. AMP: Antibody Mediated Prevention Laboratory-made antibodies, modeled after antibodies produced naturally by long-term non-progressors 2 years long and involves 10 IV infusions of the antibodies The study is open to cisgender MSM and transpeople who have sex with men who are HIV uninfected and years old. The Fenway Institute is 95% enrolled and has put a hold on new screening visits. Discover: Comparing daily oral Truvada (FTC/TDF) vs Descovy (FTC/TAF) Descovy is FDA-approved for HIV treatment, but not yet for PrEP. 2 year long with an optional 3 rd year unblinded phase in which participants have the option to stay on Descovy for PrEP for an additional year (contingent on FDA approval). Descovy may have fewer side effects than Truvada. The study is no longer enrolling new participants.
50 Modern HIV Treatment
51 Modern HIV Treatment 20-year-old newly diagnosed HIV-positive adult started immediately on ART has a life expectancy approaching that of the general population Antiretroviral therapy (ART) using a preferred regimen is recommended for all HIV-infected individuals, regardless of CD4 T-lymphocyte cell count, to reduce the morbidity and mortality associated with HIV infection (Samji, H, Cescon, A, Hogg, RS et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013; 8: e81355)
52 Summary PrEP prescribing guidelines US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States Available from:
53 A pill a day keeps HIV away
54 South Africa
55 South Africa
56 South Africa
57 A pill a day keeps HIV away
PrEP in the Real World: Clinical Case Studies
PrEP in the Real World: Clinical Case Studies Kevin L. Ard, MD, MPH April 30, 2015 Massachusetts General Hospital, National LGBT Health Education Center Continuing Medical Education Disclosure Program
More informationCase Studies in PrEP Management. Kevin L. Ard, MD, MPH Massachusetts General Hospital, National LGBT Health Education Center April 15, 2016
Case Studies in PrEP Management Kevin L. Ard, MD, MPH Massachusetts General Hospital, National LGBT Health Education Center April 15, 2016 Continuing Medical Education Disclosure Program Faculty: Kevin
More informationGuidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft:
Guidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft: 10-2-2015 Clinical studies demonstrate that when a person without HIV infection takes
More informationImportant Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP)
Important Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) For Healthcare Providers About Emtricitabine/Tenofovir Disoproxil
More informationImportant Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. For Healthcare Providers
Important Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication For Healthcare Providers About TRUVADA for a PrEP Indication INDICATION AND PRESCRIBING CONSIDERATIONS TRUVADA,
More informationDisclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.
Disclosure PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION I have no financial interest in and/or affiliation with any external organizations in relation to this CE program. DaleMarie Vaughan, PharmD
More informationOne daily pill can help prevent HIV. TRUVADA for PrEP, together with safer sex practices, can mean better protection.
TRUVADA for PrEP is a prescription medicine that can help reduce the risk of getting HIV-1 through sex, when taken every day and used together with safer sex practices. TRUVADA for PrEP is only for people
More informationTRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. Training Guide for Healthcare Providers
TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication Training Guide for Healthcare Providers About TRUVADA for a PrEP indication to reduce the risk of sexually acquired HIV-1 infection in high-risk
More informationEmtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers
Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers About emtricitabine/tenofovir disoproxil fumarate for HIV-1 PrEP
More informationPre-Exposure Prophylaxis (PrEP) for HIV Infection
Pre-Exposure Prophylaxis (PrEP) for HIV Infection Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health University of California Los Angeles Attending Physician UCLA Center AIDS Research
More informationGetting Prepped for PrEP. Ken Ho, MD, MPH World AIDS Day
Getting Prepped for PrEP Ken Ho, MD, MPH World AIDS Day Objectives HIV epidemiology What is PrEP? Does it Work? Who gets PrEP? How do I prescribe PrEP What to do at the first visit? What to do at follow
More informationRecent Breakthroughs in HIV Prevention for Men who Have Sex with Men and Transgender Populations
Recent Breakthroughs in HIV Prevention for Men who Have Sex with Men and Transgender Populations Kevin Ard, MD, MPH Brigham and Women s Hospital The Fenway Institute Boston, MA Funding: The New England
More informationOR: Steps you can take in the clinic to prevent HIV infections
Implementing Changes to Reduce HIV Incidence: Synergies between Public Health and Primary Care Kevin Ard, MD, MPH Brigham and Women s Hospital, Massachusetts General Hospital, and the Fenway Institute
More informationPrEP for HIV Prevention. Adult Clinical Guideline from the New York State Department of Health AIDS Institute
PrEP for HIV Prevention Adult Clinical Guideline from the New York State Department of Health AIDS Institute www.hivguidelines.org Purpose of the PrEP Guideline Raise awareness of PrEP among healthcare
More informationHIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland. An update for registered practitioners September 2017
HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland An update for registered practitioners September 2017 Key Messages HIV is a major public health challenge for Scotland with an annual average of 359
More informationKEEP LOVING. Because HIV doesn t change who you are.
KEEP LOVING. Because HIV doesn t change who you are. BIKTARVY is a complete, 1-pill, once-a-day prescription medicine used to treat HIV-1 in certain adults. BIKTARVY does not cure HIV-1 or AIDS. Please
More informationMoving beyond condoms to prevent HIV transmission. Are you Prepared for HIV PrEP?
Moving beyond condoms to prevent HIV transmission Are you Prepared for HIV PrEP? The Issues New HIV infections in the US continue Vast majority of infections are sexually acquired Condoms work but are
More informationPre-Exposure Prophylaxis (PrEP): Best Practices for Pharmacists
Pre-Exposure Prophylaxis (PrEP): Best Practices for Pharmacists Tina J Kanmaz, PharmD, AAHIVE Associate Clinical Professor Assistant Dean, Experiential Pharmacy Education St. John s University College
More informationImportant Safety Information About TRUVADA to Reduce the Risk of Getting Human Immunodeficiency Virus 1 (HIV-1) Infection
Important Safety Information About TRUVADA to Reduce the Risk of Getting Human Immunodeficiency Virus 1 (HIV-1) Infection This booklet is for adults taking TRUVADA to reduce the risk of getting HIV-1 infection.
More informationPre-Exposure Prophylaxis (PrEP) Stefanie La Manna, PhD, MPH, APRN, FNP-C, AGACNP-BC October 12, 2018
Pre-Exposure Prophylaxis (PrEP) Stefanie La Manna, PhD, MPH, APRN, FNP-C, AGACNP-BC October 12, 2018 Disclosures I have no financial disclosures to report Objectives Identify the need for HIV prevention
More informationPrEP and npep for HIV Prevention. Harry Rosado-Santos MD, FACP Associate Professor UU School of Medicine
PrEP and npep for HIV Prevention Harry Rosado-Santos MD, FACP Associate Professor UU School of Medicine Case Study A 26 y/o M presents for routine asymptomatic screening for sexually transmitted infections
More informationI M ENDING HIV PATIENT INFORMATION. endinghiv.org.au/prep
I M ENDING HIV PrEP PATIENT INFORMATION endinghiv.org.au/prep THIS BOOKLET PROVIDES YOU WITH INFORMATION ABOUT Pre-Exposure Prophylaxis (PrEP) for HIV. CONTENTS 06 Who will benefit from PrEP? 04 What is
More informationReady, set, PrEP! Renee-Claude Mercier PharmD, PhC, BCPS-AQ ID, FCCP Professor of Pharmacy and Medicine University of New Mexico
Ready, set, PrEP! Renee-Claude Mercier PharmD, PhC, BCPS-AQ ID, FCCP Professor of Pharmacy and Medicine University of New Mexico Objectives At the end of the talk the audience should be able to: Understand
More informationPre-exposure Prophylaxis and Primary Care
Pre-exposure Prophylaxis and Primary Care National Latino HIV and Hepatitis C Conference June 7 th, 2016 Allison Finkenbinder, MSN, WHNP-BC Denver Prevention Training Center Who s in the audience? Disclosures
More informationGuidelines for PrEP in PWID
Guidelines for PrEP in PWID Any use of injection drugs (past 6 months) AND Any sharing of injection equipment OR participation in methadone, naloxone, or buprenorphine treatment program (past 6 months)
More informationPrEP for Women: HIV Prevention in Family Planning Settings
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention PrEP for Women: HIV Prevention in Family Planning Settings Dawn K. Smith, MD, MS, MPH Division of HIV/AIDS Prevention dsmith1@cdc.gov
More informationThe HIV Prevention Pill: The State of PrEP Science and Implementation. James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE
The HIV Prevention Pill: The State of PrEP Science and Implementation James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE Overview 1. The Basics 2. A review of the science 3. An update
More informationYou matter and so does your health.
DESCOVY is a prescription medicine that is used together with other HIV-1 medicines to treat HIV-1 in people who weigh at least 77 lbs (35kg). DESCOVY does not cure HIV-1 or AIDS. Do not use DESCOVY to
More informationAttendees will be able to:
A. Kay Kalousek, DO, MS, FACOFP kaysdroid@gmail.com April 21, 2017 Attendees will be able to: List strategies for prevention of HIV infection Explain the pharmacology of TDF/FTC related to PrEP Assess
More informationSouth African Guidelines for the Safe Use of. Dr. Oscar Radebe
South African Guidelines for the Safe Use of PrEP in MSM Dr. Oscar Radebe Background Globally MSM(men who have sex with men) have been disproportionately at high risk of HIV transmission. Biological &
More information-decreased bone Adherence iprex study. -protective effect
HIV Pre-Exposure Prophylaxi is (PrEP): A brief guide for providers Daily emtricitabine/tenofovir (Truvada ) is safe and effectivee for reducing the risk of HIV acquisition in sexually active men and women
More informationPre exposure Prophylaxis (PrEP): Stepping Up HIV Prevention
Pre exposure Prophylaxis (PrEP): Stepping Up HIV Prevention Dawn K. Smith, MD, MS, MPH Centers for Disease Control and Prevention The findings and conclusions in this presentation have not been formally
More informationGilead Announces Data Demonstrating Non-Inferiority of Once-Daily Descovy vs. Once-Daily Truvada for Prevention of HIV Infection
Gilead Announces Data Demonstrating Non-Inferiority of Once-Daily Descovy vs. Once-Daily Truvada for Prevention of HIV Infection March 6, 2019 DISCOVER Trial Meets Primary and Secondary Endpoints and Will
More informationFind both sets of guidelines on nyc.gov by searching HIV PrEP and PEP. Per CDC Guidelines, PrEP may be appropriate for the following populations:
PrEP Provider FAQs 1. What is PrEP? PrEP is short for pre-exposure prophylaxis. It is the use of antiretroviral medication to prevent acquisition of HIV infection. PrEP is used by HIV uninfected people
More informationPREVENTION OF HIV IN THE TIMES OF PREP. Daniela Chiriboga, MD Florida Department of Health in Polk County
PREVENTION OF HIV IN THE TIMES OF PREP Daniela Chiriboga, MD Florida Department of Health in Polk County MAKING THE CASE FOR PREVENTION The Epidemic in Florida Population in 2014: 19.6 million (3 rd in
More informationHIV Prevention Pearls
HIV Prevention Pearls Meghan Rothenberger, MD Assistant Professor Division of Infectious Diseases University of Minnesota Director, Youth and AIDS Projects October 27, 2017 Disclosure Information I have
More informationPrEP for Women. Together, we can change the course of the HIV epidemic one woman at a time.
PrEP for Women Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is PrEP? PrEP stands for Pre- Exposure Prophylaxis: Prophylaxis: Taking
More informationHow to order generic PrEP online Find a doctor who prescribes PrEP Learn how to prescribe PrEP Information for doctors. What is PrEP?
4 What is PrEP? 6 Who will benefit from PrEP? 7 Men (cis or trans) and trans women who have sex with men Partners of people living with HIV 8 Take the quiz: Is PrEP right for me? What are the options for
More informationREVIEW OF PREP GUIDELINES: A PRIMER FOR THE PRIMARY CARE PRACTITIONER ANTONIO E. URBINA, MD. PrEP Webinar Series
REVIEW OF PREP GUIDELINES: A PRIMER FOR THE PRIMARY CARE PRACTITIONER ANTONIO E. URBINA, MD PrEP Webinar Series Disclosure Speaker s Bureau: Gilead, VIIV, BMS, Merck, Serono LEARNING OBJECTIVES: 1. Review
More informationPrEP in Scotland. PrEP. in Scotland. PrEP. PrEP. PrEP. PrEP is a combination pill that prevents HIV.
PrEP in Scotland PrEP PrEP PrEP PrEP is a combination pill that prevents HIV. 1 Contents Introduction 3 What is PrEP 3 Who should take PrEP 4 Getting PrEP in Scotland 5 Side effects and interactions with
More informationSFAF CLINICAL PROTOCOLS
SFAF CLINICAL PROTOCOLS Page 1 of Supersedes Date: December 31, 2016 Original Date: August 20, 2014 Version: 03 Policy Section: Patient Care Non-Occupational Post Exposure Prophylaxis Program Back ground:
More informationDrug development in relation to PrEP and the PROUD study
Drug development in relation to PrEP and the PROUD study David Dolling Medical Statistician MRC Clinical Trials Unit 18 th October 2012 What is PrEP? - Pre-exposure Prophylaxis A strategy that uses antiretrovirals
More informationHIV PrEP in Ireland. Information booklet for people who are accessing PrEP themselves or are considering accessing PrEP
HIV PrEP in Ireland Information booklet for people who are accessing PrEP themselves or are considering accessing PrEP The HSE Sexual Health and Crisis Pregnancy Programme (SHCPP) and the HIV PrEP working
More informationThe HIV Prevention Pill: The State of PrEP Science and Implementation
The HIV Prevention Pill: The State of PrEP Science and Implementation James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE December 11 th, 2014 Overview 1. The Basics 2. A review of the
More informationImportant Safety Information for Adolescents Who Don t Have HIV
Important Safety Information for Adolescents Who Don t Have HIV This booklet tells you about: HIV The medicine emtricitabine/tenofovir disoproxil fumarate for HIV-1 PrEP What you need to do while taking
More informationHIV Prevention among Women
HIV Prevention among Women Assistant Professor of Medicine Division of Infectious Diseases Baylor College of Medicine Disclosures: Gilead Sciences - Scientific Advisory Board; Investigatorinitiated research
More informationCONTENTS. New Zealand s personal importation scheme for medicines. What is PrEP? Who will benefit from PrEP? Sex between men
CONTENTS 4 What is PrEP? 6 Who will benefit from PrEP? Sex between men 7 Sex between men and women 8 What happens when I start on PrEP? 9 What if I want to stop using PrEP? Where can I get PrEP in New
More informationThe role of Integrase Inhibitors during HIV prevention
The role of Integrase Inhibitors during HIV prevention Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint 2nd Global HIV Clinical Forum: Integrase Inhibitors Paris July 22th
More informationArizona State Office of Rural Health Webinar Series
Arizona State Office of Rural Health Webinar Series Mute your phone &/or computer microphone Time is reserved at the end for Q&A Please fill out the post-webinar survey Webinar is being recorded Recording
More informationIf you are a man that ONLY has sex with women this may not be the brochure for you.
If you are a man that ONLY has sex with women this may not be the brochure for you. To find resources that best meet your needs check out the following website: http://www.cdc.gov/men Whether you are gay,
More informationPatient Information VIREAD (VEER-ee-ad) (tenofovir disoproxil fumarate) tablets and oral powder
Patient Information VIREAD (VEER-ee-ad) (tenofovir disoproxil fumarate) tablets and oral powder Read this Patient Information before you start taking VIREAD and each time you get a refill. There may be
More informationObjectives. HIV in the Trenches HIV Update for the Primary Care Provider, An Overview The HIV Continuum of Care.
1:30 2:30pm HIV Update SPEAKER Gordon Dickinson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Gordon Dickinson, MD, has no financial relationships
More informationPrEP: Pre Exposure Prophylaxis
PrEP: Pre Exposure Prophylaxis Lyn Stevens, NP, MS, ACRN Deputy Director Office of the Medical Director NYS Department of Health, AIDS Institute Faculty Disclosure Lyn Stevens No relationships to disclose
More informationPrEP Basics: A Patient-Centered Approach to Providing PrEP
www.med-iq.com www.projectinform.org 12/18/2017 1 Incidence data help inform the need for local and state HIV services. However, individuals may be more vulnerable to HIV beyond what incidence data indicate.
More informationHIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland
HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland An update for registered practitioners November 2017 Rationale for resource This resource is designed to support registered practitioners involved in
More informationRoy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City
PrEP 2013 Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Slide #2 U.S.: New HIV Infections Per Year ~50,000
More informationPrEP and Behavioral Strategies for HIV Prevention. Douglas Krakower, MD January 30, 2014
PrEP and Behavioral Strategies for HIV Prevention Douglas Krakower, MD January 30, 2014 Potential Competing Interests Dr. Krakower: investigator-initiated research regarding HIV prevention National Institutes
More informationHIV & THE MEDICAL HOME A NEW FRONT FOR GETTING TO ZERO. Brent K. Sugimoto, MD, MPH Kaiser Permanente. 29th Annual East Bay HIV Update June 3, 2016
HIV & THE MEDICAL HOME A NEW FRONT FOR GETTING TO ZERO 29th Annual East Bay HIV Update June 3, 2016 Brent K. Sugimoto, MD, MPH Kaiser Permanente Photo Credit: C. GoldsmithContent Providers: CDC/ C. Goldsmith,
More informationHIV. The Role of Pre-Exposure Prophylaxis (PrEP) for the Prevention of HIV. Brief History of HIV AIDS. Global HIV Infection.
The Role of Pre-Exposure Prophylaxis (PrEP) for the Prevention of HIV HIV Sarah Kemink, PharmD, AAHIVP WMSHP Spring Seminar 5/05/2015 AIDS CD4 less than 200 +/- AIDS-defining illness Most common: Candidiasis
More informationPre-Exposure Prophylaxis: The New Frontier of Prophylaxis Against HIV Infection
Pre-Exposure Prophylaxis: The New Frontier of Prophylaxis Against HIV Infection William F. Ryan Community Health Network PrEP Network Coordinator: Trevor Hedberg, MPH, CPH Supervising Health Educator:
More informationPrEP 201: Beyond the Basics
NORTHWEST AIDS EDUCATION AND TRAINING CENTER PrEP 201: Beyond the Basics Joanne Stekler, MD MPH Associate Professor of Medicine University of Washington February 19, 2015 Disclosures and Disclaimers I
More informationFast-Track Your PrEP Knowledge. Jonathan Fritz PrEP Coordinator MDHHS Division of HIV and STD Programs
Fast-Track Your PrEP Knowledge Jonathan Fritz PrEP Coordinator MDHHS Division of HIV and STD Programs Session objectives Increase knowledge of the basics of PrEP and clinical procedures Identify financial
More informationPrEP Home Checklist v1.0
PrEP Home Checklist v1.0 Every Visit o Risk Reduction Counseling o Appropriate referrals and follow-ups (SW, Pharmacy, et al.) o For those on PrEP: o Assessment of PrEP adherence, side effects, ongoing
More informationWhat is the most important information I should know about tenofovir? What should I discuss with my healthcare provider before taking tenofovir?
1 of 6 6/10/2016 4:33 PM Generic Name: tenofovir (ten OF oh vir) Brand Name: Viread What is tenofovir? Tenofovir is an antiviral medicine that prevents human immunodeficiency virus (HIV) or hepatitis B
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationPre-Exposure Prophylaxis (PrEP) and the Governor s Plan to End AIDS: What Every Clinician Needs to Know
Pre-Exposure Prophylaxis (PrEP) and the Governor s Plan to End AIDS: What Every Clinician Needs to Know ANTONIO E. URBINA, MD Medical Director Associate Professor of Medicine Mt. Sinai Hospital Disclosure
More informationAntiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?
Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Lut Van Damme 11 Oct 2012 1 Disclaimer Gilead donated the study product for the FEM-PrEP trial I participated
More informationPre-exposure prophylaxis (PrEP)
FACTSHEET Pre-exposure prophylaxis (PrEP) Summary Pre-exposure prophylaxis, or PrEP, is a way for an HIV-negative person who is at risk of HIV infection to reduce their risk of becoming infected with HIV.
More informationAn International Antiviral Society-USA
Doug Campos-Outcalt, MD, MPA University of Arizona, Phoenix dougco@email.arizona. edu A look at new guidelines for HIV treatment and prevention Start antiretroviral therapy as soon as possible after HIV
More informationQuick Study: Sexually Transmitted Infections
Quick Study: Sexually Transmitted Infections Gonorrhea What is it: A bacterial infection of the genitals, anus, or throat. How common: The CDC estimates 820,000 people in the United States get Gonorrhea
More informationClinical Education Initiative PRE-EXPOSURE PROPHYLAXIS. Speaker: Antonia Urbina, MD
Clinical Education Initiative Support@ceitraining.org PRE-EXPOSURE PROPHYLAXIS Speaker: Antonia Urbina, MD 9/6/2017 Pre-Exposure Prophylaxis [video transcript] 1 00:00:07,480 --> 00:00:09,139 I mean we're
More informationAustralasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines
GUIDELINES Journal of Virus Eradication 2017; 3: 168 184 Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines Edwina Wright 1 3 *,
More informationThe Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN
The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN 1 Ongoing HIV transmission despite expanding access to ART SA 18 16 14 12 10 8 6 4 2 0 Treatment exposure
More informationDescovy. (emtricitabine, tenofovir alafenamide) New Product Slideshow
Descovy (emtricitabine, tenofovir alafenamide) New Product Slideshow Introduction Brand name: Descovy Generic name: Emtricitabine, tenofovir alafenamide (TAF) Pharmacological class: Nucleoside analog reverse
More informationPrEP Dosing Strategies
PrEP Dosing Strategies Outline o Background PrEP absorption and tissue penetration o Oral versus topical o Lead in and lead out dosing Time to protection o Cycling on and off PrEP o Balancing toxicity
More informationAre you PrEP(ared)? PrEP Basics & Knowledge Dissemination
Are you PrEP(ared)? PrEP Basics & Knowledge Dissemination Harlan Pruden Educator, Chee Mamuk, Aboriginal Program BC Center for Disease Control, Clinical Prevention Services Sḵwx on the traditional, ancestral
More informationPATIENT INFORMATION VIREAD
PATIENT INFORMATION VIREAD (VEER-ee-ad) (tenofovir disoproxil fumarate) tablets and oral powder Read this Patient Information before you start taking VIREAD and each time you get a refill. There may be
More informationPrEP for HIV prevention. Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint
PrEP for HIV prevention Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint DISCLOSURES I have received a research grant from Gilead Sciences awarded to my institution I have
More informationPart VI.2 Elements for a Public Summary
Part VI.2 Elements for a Public Summary Part VI.2.1 Overview of disease epidemiology Human immunodeficiency virus (HIV)-1 infection: HIV that causes acquired immunodeficiency syndrome (AIDS), has become
More informationPREP IN PRIMARY CARE TRACY SALAMEH RN, BSN, ACRN HIV CLINICAL SPECIALIST DAKOTA AIDS EDUCATION AND TRAINING CENTER
PREP IN PRIMARY CARE TRACY SALAMEH RN, BSN, ACRN HIV CLINICAL SPECIALIST DAKOTA AIDS EDUCATION AND TRAINING CENTER THE NEED FOR CONTINUED HIV PREVENTION Estimated new HIV infections in the US for the most
More informationPre Exposure Prophylaxis Health Program
MAGNET CLINICAL PROTOCOLS Pre Exposure Prophylaxis Health Program Page 1 of Supersedes Date: October 7, 2018 Original Date: August 20, 2014 Version: 09 Policy Section: Patient Care Back ground: The advent
More informationPatient Information. VIREAD (VEER-ee-ad) (tenofovir disoproxil fumarate) tablets. (tenofovir disoproxil fumarate) oral powder
Patient Information tablets oral powder Read this Patient Information before you start taking VIREAD and each time you get a refill. There may be new information. This information does not take the place
More informationMANAGEMENT OF SEXUAL EXPOSURE TO HIV: PEPSE
Sandyford Protocols MANAGEMENT OF SEXUAL EXPOSURE TO HIV: PEPSE www.hiv-druginteractions.org If you require information on occupational exposure to blood borne viruses, including HIV, please refer to the
More informationHIV Prevention Strategies HIV Pre-exposure prophylaxis
HIV Prevention Strategies HIV Pre-exposure prophylaxis Michael Martin, MD, MPH Director HIV Research Program Thailand MOPH U.S. CDC Collaboration The findings and conclusions in this presentation are those
More informationdetermine need but regimen does not change based on risk factor ED medicine attending meets
HIV PEP Guidelines after Sexual Assault Harborview Medical Center January 2015 Initial risk assessment and discussion with patient about risk and PEP is by clinician who does exam (SANE, Ob-Gyn resident,
More informationPre-exposure Prophylaxis. Robert M Grant October 2014
Pre-exposure Prophylaxis Robert M Grant October 2014 The HIV Pandemic 2.3 Million New HIV Infections in 2012 39% in Young People (ages 15-24) The HIV Pandemic 1.6 Million Started Therapy in 2012 1.4 New
More informationCATIE STATEMENT. on the use of oral pre-exposure prophylaxis (PrEP) as a highly effective strategy to prevent the sexual transmission of HIV
CATIE STATEMENT on the use of oral pre-exposure prophylaxis (PrEP) as a highly effective strategy to prevent the sexual transmission of HIV The consistent and correct use of oral Truvada as pre-exposure
More informationPre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention
Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention New and Emerging Biomedical HIV Prevention Interventions Vaccines Vaginal microbicides Pre-exposure
More informationPre-exposure Prophylaxis for HIV Prevention
Mountain West AIDS Education and Training Center Pre-exposure Prophylaxis for HIV Prevention Concerns about PrEP: Sexual Behavior and STIs Joanne Stekler, MD MPH May 19, 2016 This presentation is intended
More informationHIV PREVENTION WITH PRE-EXPOSURE PROPHYLAXIS: A PRIMER FOR PHARMACISTS. Speaker: Susan MK Lee, PharmD, BCPS, CDE
Clinical Education Initiative Support@ceitraining.org HIV PREVENTION WITH PRE-EXPOSURE PROPHYLAXIS: A PRIMER FOR PHARMACISTS Speaker: Susan MK Lee, PharmD, BCPS, CDE 12/13/2016 HIV Prevention with Pre-Exposure
More informationPATIENT INFORMATION VIREAD (VEER-ee-ad) (tenofovir disoproxil fumarate) tablets and oral powder Read this Patient Information before you start taking
PATIENT INFORMATION VIREAD (VEER-ee-ad) (tenofovir disoproxil fumarate) tablets and oral powder Read this Patient Information before you start taking VIREAD and each time you get a refill. There may be
More informationPATIENT INFORMATION EMTRIVA
PATIENT INFORMATION EMTRIVA (em-treev -ah) capsules EMTRIVA oral solution Generic name: emtricitabine (em tri SIT uh bean) Read the Patient Information that comes with EMTRIVA before you start using it
More informationThe Door is Open PrEP in Practice. Antonio E. Urbina, MD Associate Professor of Medicine Icahn School of Medicine Mount Sinai Hospital
The Door is Open PrEP in Practice Antonio E. Urbina, MD Associate Professor of Medicine Icahn School of Medicine Mount Sinai Hospital Learning Objectives As a result of participating in this activity,
More informationHIV Pre-Exposure Prophylaxis (PrEP)
HIV Pre-Exposure Prophylaxis (PrEP) A Crash Course For General Practitioners Vincent Cornelisse BSc(Hons) MBBS FRACGP FAChSHM(RACP) Sexual Health Physician Prahran Market Clinic & Melbourne Sexual Health
More informationFaculty: Relationships with financial sponsors: Speakers Bureau/Honoraria: Advisory board/consulting Fees:
Faculty/Presenter Disclosure Faculty: Joss de Wet Relationships with financial sponsors: Speakers Bureau/Honoraria: Gilead, ViiV, Merck. Advisory board/consulting Fees: Gilead, ViiV, Merck. Dr Joss de
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationAddressing STIs among MSM: A Clinical and Public Health Update
Addressing STIs among MSM: A Clinical and Public Health Update Kevin L. Ard, MD, MPH National LGBT Health Education Center, Fenway Institute Infectious Disease Division, Massachusetts General Hospital
More informationUsing PrEP as Harm Reduction. Iman Little, MPH Team Lead, Preventative Services Chicago Center for HIV Elimination
Be PrEPared! Using PrEP as Harm Reduction Iman Little, MPH Team Lead, Preventative Services Chicago Center for HIV Elimination Ricky Hill, MA, PhD candidate Team Lead, Community Partnerships and Engagement
More informationTrends in Sexually Transmitted Infections (STIs) C. Junda Woo, MD, MPH, Medical Director San Antonio Metropolitan Health District June 3, 2017
Trends in Sexually Transmitted Infections (STIs) C. Junda Woo, MD, MPH, Medical Director San Antonio Metropolitan Health District June 3, 2017 1 Speaker Disclosure Dr. Woo has disclosed that she has no
More informationA publication for men and transgender women who have sex with men. Is taking PrEP the right choice for you? your life matters
A publication for men and transgender women who have sex with men Pre-exposure Prophylaxis Is taking PrEP the right choice for you? your life matters OCTOBER 2013 Check out our four videos on PrEP as well!
More information